Current Report · Items 5.07 · 8-K
Sunshine Biopharma Inc.
SBFMNASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On September 15, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc.…
Company context
We are a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. We have two wholly owned subsidiaries: (i) Nora Pharma Inc., a Canadian corporation, through which we currently have 60 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc., a Canadian corporation through which we develop and sell OTC supplements.
Current securities
Historical securities (6)
SBFMOTC · EQUITY · Historical · closed Feb 1, 2019SBFMOTC · EQUITY · Historical · closed Apr 6, 2020SBFMOTC · EQUITY · Historical · closed Feb 9, 2022SBFMDOTC · EQUITY · Historical · closed Mar 1, 2019SBFMDOTC · EQUITY · Historical · closed May 1, 2020SBFMDOTC · EQUITY · Historical · closed Feb 15, 2022
Disclosure sections
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of
Security Holders.
On September 15, 2026, Dr. Steve N. Slilaty, as
the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by
written consent authorizing the Company’s board of directors to effect a reverse split of the Company’s common in a ratio
of up to 1-for-20, with the board of directors having the discretion as to whether or not the reverse split is to be effected, and with
the exact ratio of any reverse split to be set at a whole number up to 1-for-20 as determined by the board in its discretion. The shareholder
consent will be effective 20 days after the definitive information statement relating to such consent is mailed to stockholders. Dr. Slilaty,
who is the Company’s chief executive officer, holds approximately 97% of the total voting power of the Company’s stockholders.